ClinicalTrials.gg
Not yet recruitingNCT07925294Updated Nov 9, 2026

The Impact of Myofunctional Therapy on Children With Sleep Apnea and Obesity

An interventional study of Myofunctional therapy in Obstructive Sleep Apnea (OSA) and Obesity, sponsored by Université Catholique de Louvain. Not yet recruiting. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Université Catholique de Louvain · Not applicable, Interventional, and Treatment

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Study summary

Obstructive sleep-disordered breathing (oSDB) in children ranges from primary snoring to OSAHS and has cardiovascular and cognitive-behavioral consequences. In obese children, prevalence reaches 13-59%, and obesity and OSAHS reinforce each other through mechanical and metabolic pathways. Institutional weight-loss programs are first-line treatment but leave about 20% of children with persistent oSDB. Since tongue neuromuscular function supports upper-airway patency and myofunctional therapy reduces the pediatric apnea-hypopnea index by approximately 43%, this protocol tests whether adding myofunctional rehabilitation to a weight-loss program further improves outcomes in obese children with OSAHS, with follow-up at three months.

02

Conditions studied

  • Obstructive Sleep Apnea (OSA) and Obesity

Keywords

  • sleep apnea
  • obesity
  • children
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 62 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Université Catholique de Louvain is the lead sponsor of 154 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being aged from 10 to 17 years
  • Having a above 97th percentile according to age/sex, or above 35 for 17 year old children

Exclusion criteria

Exclusion Criteria:

  • Any reason preventing participation to the intervention protocol or the assessments (e.g., oral pain, severe cognitive impairment, non-cooperation, unable to read)
  • Being already involved in an oropharyngeal rehabilitation protocol
  • Any neuromuscular syndrome or cranio-facial malformation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Intervention

    Supervised myofunctional therapy in addition to standard care (weight loss program)

    Other: Myofunctional therapy

  • No intervention
    Control

    Standard care (weight loss program)

Interventions

  • OtherMyofunctional therapy

    3 to 5 sessions of 20-30 min. each per week, for 3 months

06

What researchers measure

Primary outcomes

  1. Apnea-hypopnea index (AHI)

    Sleep polygraphy

    Time frame: Throughout the entire study, during approximately 4 years

Secondary outcomes

  1. Tongue strength assessment

    Maximal pressure exerted by the tongue against an air-filled bulb (in kPa) in protrusion, elevation, and during swallowing.

    Time frame: Throughout the entire study, during approximately 4 years

  2. Tongue morphology assessment

    Submental ultrasound in frontal and sagittal plane, to assess the thickness of tongue muscles (cm)

    Time frame: Throughout the entire study, during approximately 4 years

  3. Tongue mobility score

    Motricité Bucco-Linguo-Faciale (MBLF) test, where several movements are scored between 0 and 3 regarding muscular contraction or symmetry.

    Time frame: Throughout the entire study, during approximately 4 years

  4. Sleep quality questionnaire

    The Pediatric Sleep Questionnaire will be administered to parents. Items are answered "yes", "no", or "I don't know", and higher scores indicate more signs of obstructive sleep-disordered breathing.

    Time frame: Throughout the entire study, during approximately 4 years

Other outcomes

  1. Semi-structured interview

    A semi-structured interview will be conducted to collect qualitative data on sleep quality

    Time frame: Throughout the entire study, during approximately 4 years

  2. Tongue frenulum assessment

    Tongue range of motion ratio, reflecting the restriction imposed by the lingual frenulum. It is computed as the maximal mouth opening with the tongue tip held at the incisive papilla (mm) divided by the maximal mouth opening (mm).

    Time frame: Throughout the entire study, during approximately 4 years

  3. Breathing pattern questionnaire

    Mouth breathing questionnaire from Abreu et al., considered positive if two major items, or one major and two minor items, are answered "yes"

    Time frame: Throughout the entire study, during approximately 4 years

  4. Temporomandibular (TMD) pain screener

    This questionnaire will be used to assess the presence of any temporomandibular joint disorder.

    Time frame: Throughout the entire study, during approximately 4 years

  5. 3 questions/temporomandibular (3Q/TMD) questionnaire

    This questionnaire will be used to assess the presence of any temporomandibular joint disorder.

    Time frame: Throughout the entire study, during approximately 4 years

  6. Adherence to rehabilitation protocol

    Adherence will be monitored through a participation log of the rehabilitation sessions.

    Time frame: Throughout the entire study, during approximately 4 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2030, 45 months later.

Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 623 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 9, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Sep 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07925294
Collaborators
Centre Médical Pédiatrique Clairs Vallons
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

William Poncin, Professor
Contact
william.poncin@uclouvain.be
0471 90 66 23

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion